You are here

Article Text

Article menu
Download PDFPDF
Research Article
Nomifensine in parkinsonism.
  1. P F Teychenne,
  2. D M Park,
  3. L J Findley,
  4. F C Rose,
  5. D B Calne

    Abstract

    Nomifensine, a tetrahydroisoquinolone antidepressant which facilitates dopaminergic and noradrenergic transmission, was studied in 28 Parkinsonism patients most of whom were also receiving conventional medications. Double-blind evaluations revealed a moderate therapeutic action at a mean dose level of 150 mg daily. Adverse reactions were encountered, similar to those identical by levodopa.

    https://doi.org/10.1136/jnnp.39.12.1219

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.